Early high-dosage atorvastatin treatment improved serum immune-inflammatory markers and functional outcome in acute ischemic strokes classified as large artery atherosclerotic stroke: A randomized trial
| Autor: | Vittoriano Della Corte, Domenico Gerardo Iacopino, Carlo Maida, Danilo Di Bona, Irene Simonetta, Rosaria Pecoraro, Antonio Pinto, Rosario Maugeri, Francesca Corpora, Antonino Tuttolomondo, Valentina Arnao, Domenico Di Raimondo |
|---|---|
| Přispěvatelé: | Tuttolomondo A., Di Raimondo D., Pecoraro R., Maida C., Arnao V., Corte V.D., Simonetta I., Corpora F., Di Bona D., Maugeri R., Iacopino D.G., Pinto A. |
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
P-selectin Atorvastatin Interleukin-1beta 030204 cardiovascular system & hematology law.invention Brain Ischemia Brain ischemia Cerebral circulation 0302 clinical medicine Randomized controlled trial law Intracranial Arteriosclerosi Stroke Inflammation Mediator biology Clinical Trial/Experimental Study General Medicine Middle Aged Intracranial Arteriosclerosis Intercellular Adhesion Molecule-1 Interleukin-10 P-Selectin Acute Disease Cardiology Female Inflammation Mediators medicine.symptom E-Selectin Research Article medicine.drug Human medicine.medical_specialty Vascular Cell Adhesion Molecule-1 Inflammation 03 medical and health sciences Internal medicine medicine Humans cardiovascular diseases Interleukin 6 Aged business.industry Interleukin-6 Tumor Necrosis Factor-alpha Biomarker medicine.disease Physical therapy biology.protein business Biomarkers 030217 neurology & neurosurgery |
| Zdroj: | Medicine |
| Popis: | Statins have beneficial effects on cerebral circulation and brain parenchyma during ischemic stroke and reperfusion. The primary hypothesis of this randomized parallel trial was that treatment with 80 mg/day of atorvastatin administered early at admission after acute atherosclerotic ischemic stroke could reduce serum levels of markers of immune-inflammatory activation of the acute phase and that this immune-inflammatory modulation could have a possible effect on prognosis of ischemic stroke evaluated by some outcome indicators. We enrolled 42 patients with acute ischemic stroke classified as large arteries atherosclerosis stroke (LAAS) randomly assigned in a randomized parallel trial to the following groups: Group A, 22 patients treated with atorvastatin 80 mg (once-daily) from admission day until discharge; Group B, 20 patients not treated with atorvastatin 80 mg until discharge, and after discharge, treatment with atorvastatin has been started. At 72 hours and at 7 days after acute ischemic stroke, subjects of group A showed significantly lower plasma levels of tumor necrosis factor-α, interleukin (IL)-6, vascular cell adhesion molecule-1, whereas no significant difference with regard to plasma levels of IL-10, E-Selectin, and P-Selectin was observed between the 2 groups. At 72 hours and 7 days after admission, stroke patients treated with atorvastatin 80 mg in comparison with stroke subjects not treated with atorvastatin showed a significantly lower mean National Institutes of Health Stroke Scale and modified Rankin scores. Our findings provide the first evidence that atorvastatin acutely administered immediately after an atherosclerotic ischemic stroke exerts a lowering effect on immune-inflammatory activation of the acute phase of stroke and that its early use is associated to a better functional and prognostic profile. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|